Nautilus Biotechnology (NAUT) Long-Term Investments (2020 - 2026)

Nautilus Biotechnology has reported Long-Term Investments for 7 years, with the latest figure at $45.2 million in Q2 2026.

• Quarterly Long-Term Investments rose 42.73% year-over-year to $45.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $45.2 million (up 42.73% YoY) and the FY2025 annual result came in at $52.7 million, down 30.97% from the prior year.
• Long-Term Investments retreated to $45.2 million in Q2 2026 per NAUT's latest filing, from $47.5 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $134.6 million in Q1 2023 and troughed at $24.9 million in Q1 2022.
• A 5-year average of $69.6 million and a median of $65.6 million in 2022 frame the typical range for Long-Term Investments.
• The widest YoY moves for Long-Term Investments: up 689.01% in 2022, down 83.34% in 2022.
• Over 5 years, Long-Term Investments stood at $129.2 million in 2022, then slipped by 29.82% to $90.6 million in 2023, then dropped by 15.71% to $76.4 million in 2024, then sank by 30.97% to $52.7 million in 2025, then retreated by 14.38% to $45.2 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $45.2 million, $47.5 million, and $52.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.